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Purpose of the study
Achieving and maintaining an optimal plasma concentra-
tion of antiretroviral drugs is essential for minimising the
risks of mother-to-child transmission of HIV. However,
altered pharmacokinetics during pregnancy means there
is a real risk of both under- and over-dosing of medica-
tions. The aim of this study is to describe atazanavir/riton-
avir (ATV/r) pharmacokinetics during pregnancy.
Methods
Pregnant HIV-positive women receiving ATV/r as part of
their routine prenatal care were prospectively enrolled in
this open labelled study. Plasma concentrations were
determined in the first (T1), second (T2) and third (T3)
trimester. Post-partum sampling was performed where
applicable. High-performance liquid chromatography
(HPLC), with a limit of quantification of 250 ng/ml, was
used to measure ATV/r concentrations.
Summary of results
From January 2007, 14 women were enrolled in the study.
All received ATV/r at standard dose of one tablet once a
day. 5/14 women were started on ATV/r during preg-
nancy. The median gestation at initiation was 24 weeks
(range 13 to 25 weeks). Nine women were on HAART
prior to pregnancy, six of whom were virally suppressed
on enrolment in the study. Median baseline CD4 count
was 367 (range 176 to 869). Median baseline viral load
was <50 cpm (range <50 to 23,544). 11/14 were black
African and the average age was 31 years (range 26 to 34).
TDM was drawn in 5/14 in T1; 7/14 in T2; 8/14 in T3 and
3/14 PP (≤ 12 weeks). Most samples tested were above the
MEC of 150 ng/ml with values ranging between 472 ng/
ml (T2 sample) and 3,400 ng/ml (T1 sample). 2/23 sam-
ples were below the lower limit of quantification (62 ng/
ml). There was no correlation between TDM levels and
viral load.
Conclusion
ATV/r concentrations showed a considerable degree of
inter-patient variability in our sample. However, the
standard dose did achieve therapeutic levels both ante-
partum and post-partum in the majority of cases, suggest-
ing the current regimen is appropriate in pregnancy.
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